Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT EBITDA Margin
EBITDA as a percentage of revenue.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to -16.9%
EBITDA Margin was -16.9% in Q2 FY2026, up 13.9 pp from a year earlier. On a trailing-twelve-month basis it was -5.2%, up 42.1 pp year over year. Over 3 fiscal years it widened by 83.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -8.9% for the fiscal year ending Dec 2026, up from -10.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -16.9%+3.4 pp QoQ
- Last fiscal yearDec 2025
- -10.8%+61.2 pp YoY
- LTMJun 2026
- -5.2%+42.1 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -10.8%
- Year-over-year change
- +61.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -10.8% | +61.2pp |
| FY2024 | 2024-12-31 | -71.9% | +39.2pp |
| FY2023 | 2023-12-31 | -111.2% | -16.6pp |
| FY2022 | 2022-12-31 | -94.6% | +30.7pp |
| FY2021 | 2021-12-31 | -125.3% | — |
EBITDA Margin vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 EBITDA Margin of -5.2% is the 3rd highest of the 8 companies compared; the peer median is -40.5%.
- Its year-over-year change of +42.1 pp is the 3rd highest of 7, against a peer median of +17.8 pp.
- Over three fiscal years its change of +83.8 pp compares with a peer median of +193.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 56.1% | +0.7 pp | +5.1 pp | |
| LTM Sep 2026 | 7.3% | +27.5 pp | +333.4 pp | |
| LTM Jun 2026 | -5.2% | +42.1 pp | +83.8 pp | |
| LTM Jun 2026 | -37.5% | +8.1 pp | +167.8 pp | |
| LTM Jun 2026 | -40.5% | +584.3 pp | +435.7 pp | |
| LTM Mar 2026 | -60.1% | +4260.2 pp | +61.2 pp | |
| LTM Sep 2026 | -100.7% | -80.8 pp | +219.4 pp | |
| LTM Sep 2026 | -69878.4% | — | — | |
IRONDisc Medicine, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding ADPT) | -40.5% | +17.8 pp | +193.6 pp | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Cost of Revenue | 49.3M | 57.91M | 75.55M | 72.08M | 71.36M |
| Gross Profit | 105.04M | 127.4M | 94.72M | 106.88M | 205.62M |
| Gross Margin | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% |
| Research & Development | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
| Selling, General & Admin | 169.97M | 184.13M | 172.51M | 157.57M | 167.27M |
| Operating Expenses | 314.01M | 327.59M | 321.76M | 269.43M | 262.74M |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| EBITDA | (193.35M) | (175.21M) | (189.27M) | (128.76M) | (29.85M) |
| EBITDA Margin | -125.3% | -94.6% | -111.2% | -71.9% | -10.8% |
| Operating Income | (208.97M) | (200.19M) | (227.04M) | (162.55M) | (57.12M) |
| Operating Margin | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Interest Income | 1.67M | 4.06M | 15.53M | 14.53M | 9.44M |
| Interest Expense | 0 | 4.24M | 13.8M | 11.58M | 11.78M |
| Other Income / Expenses | 1.67M | (182K) | 1.73M | 2.95M | (2.33M) |
| Income Before Tax | (207.3M) | (200.37M) | (225.3M) | (159.6M) | (59.46M) |
| Pre-Tax Margin | -134.3% | -108.1% | -132.3% | -89.2% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.49M) | (59.5M) |
| Net Margin | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| EPS (Basic) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| EPS (Diluted) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| Weighted Avg Shares | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
| Weighted Avg Shares (Diluted) | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.